A New CEO And Perhaps A New Era At Shire: An Interview With Flemming Ornskov
Making his public debut as Shire CEO at the World Orphan Drug Congress, Flemming Ornskov talked with “The Pink Sheet” about his four-month transition period as Angus Russell’s designated successor, how his background in pediatrics may guide business development, and whether he plans to revise the specialty pharma’s business model or hew to his predecessor’s course.
You may also be interested in...
Deals Of The Week: Will Heated Competition To Buy Out Ache Laboratorios Muddy The Brazilian Waters?
Pfizer, Novartis and Abbott reportedly are battling to buy out family-owned Ache, Brazil’s leader in prescription drug sales. Plus deals involving AstraZeneca and AlphaCore, Pfizer and Bind Therapeutics and Merck and Ra Pharma.
Shire Adds To HGT Unit With Lotus Acquisition; Gets Preclinical Rare Disease Treatment
Shire makes a bolt-on acquisition that will complement both its rare disease franchise and its regenerative medicines unit.
Shire Expands Rare Disease R&D With Boston Tie-Up
Shire is teaming up with Children’s Hospital Boston to find therapies for rare pediatric diseases in a three-year collaboration that will capitalize on the strengths of both partners.